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Abstract Long-chain 3-hydroxyacyl-CoA dehydrogenase
(LCHAD) deficiency is an inborn error of fatty acid
metabolism that affects the degradation of long chain
fatty acids and causes insufficient energy production and
accumulation of toxic intermediates. The treatment
consists of a diet low in fat, with supplementation of
medium-chain triglycerides that bypass the metabolic
block. In addition, frequent feeds and extra carbohydrates
are given during febrile illnesses to reduce lipolysis.
Hence, this diet differs from the general dietary recom-
mendations for growing children. Furthermore, the Swed-
ish dietary instructions for fat intake in LCHAD
deficiency are given in grams, which differ from most
guidelines that recommend fat intake as percentage shares
of total caloric intake.
Aims: To assess growth in patients with LCHAD
deficiency, in relation to dietary treatment and to evaluate
if overweight/obesity is more common than in the normal
population.
Results: The growth velocity showed acceleration after
diagnosis and the start of treatment, followed by a period of
stable or decelerated growth. The majority of the patients
developed overweight to a greater extent than children without
LCHAD deficiency. Several patients also went through a
phase of obesity. Data on final height (FH) showed that three
out of five patients had grown according to their genetic
potential.
Conclusions: Regular and frequent follow-up and careful
monitoring of weight are essential to avoid the development
of overweight and obesity. The Swedish dietary instructions
defining fat intake in total grams per day may be an alternative
approach to achieve a moderate total caloric intake.
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EFA Essential fatty Acid
FH Final Height
FH SDS Final Height Standard Deviation Score
IUGR Intra Uterine Growth Restriction
LCF Long Chain Fatty Acid
LCHAD Long-chain 3-hydroxyacyl-CoA dehydrogenase
MTP Mitochondrial trifunctional protein
SGA Small for gestational age
TH Target Height
TH SDS Target Height Standard Deviation Score
Introduction
LCHAD deficiency (OMIM 609016) was first described
in 1989 (Wanders et al. 1989 ; Wanders et al. 1990a;
Hagenfeldt et al. 1990) in children who presented with
lethargy and hypoketotic hypoglycemia after a short
period of fasting often in association with gastroenteritis
or other febrile infections. The diagnosis is usually
established within the first year of life, often when nightly
feedings are weaned (Saudubray et al. 1999; Tyni et al.
1997; Spiekerkoetter et al. 2009a). Some patients present
with acute symptoms such as coma, cardiac arrest, and
hypoketotic hypoglycemia, while others present with
unspecific symptoms such as failure to thrive, poor weight
gain, and vomiting. Common clinical findings are liver
enlargement, muscular hypotonia, and hypertrophic car-
diomyopathy. The mortality rate is high before diagnosis
and treatment (den Boer et al. 2002). Measurements of
acylcarnitines in plasma or nonesterified dicarboxylic and
3-hydroxy fatty acids in plasma and organic acids in urine
and mutation analysis (Hagenfeldt et al. 1995; IJlst et al.
1994) are part of the diagnostic procedure. The most
common mutation is G1428C in the a-subunit of the
trifunctional protein (IJlst et al. 1996; IJlst et al. 1994;
Sims et al. 1995).
Obstetric complications such as acute fatty liver of
pregnancy, HELLP syndrome, preeclampsia and growth
retardation are common when the fetus is affected with
LCHAD deficiency, possibly as a result of placental
insufficiency (Tyni et al. 1998a; Wilcken et al. 1993; Yang
et al. 2002). The long-term outcome is variable, but a
constant feature is retinal pigmentations progressing to
impaired retinal function (Fahnehjelm et al. 2007; Tyni
et al. 1998b). Peripheral neuropathy and psychomotor delay
have been described in some patients (Bennett et al. 2000;
den Boer et al. 2002; Saudubray et al. 1999; Spiekerkoetter
et al. 2009a, b; Tyni et al. 1997; Wanders et al. 1990b).
The aim of the treatment is to minimize the necessity of
energy production from long-chain fatty acids of both
exogenous and endogenous origin, and thereby avoid
accumulation of toxic intermediates of the defective
b-oxidation. The diet, low in fat content and hence long-
chain fatty acids from normal food, is supplemented with
medium-chain triglycerides (MCT fat) and thereby
bypasses the enzymatic defect. Supplementation with
essential fatty acids is necessary to avoid deficiency
(Gillingham et al. 1999; Gillingham et al. 2003; Spieker-
koetter et al. 2009a); however, management may vary
considerably (Potter et al. 2012). To inhibit lipolysis,
frequent feeds are necessary. During catabolic events such
as febrile infections, anabolic treatment with an intravenous
glucose infusion may be necessary. Even after the diagnosis
has been established and treatment started, the patients may
have episodes of metabolic decompensation, especially
during infections or fasting, with muscle pain, muscular
hypotonia, and elevated serum CK and aminotransferases.
The Swedish dietary instructions for children with an
LCHAD deficiency differs from most international guide-
lines as they are given in grams of long-chain fatty acid
intake (Shaw and Lawson 2001) instead of as a percentage
of the total energy intake (Gillingham et al. 1999;
Gillingham et al. 2003; Spiekerkoetter et al. 2009b, 2010).
The diet in LCHAD is extreme and in disagreement with
general nutritional recommendations for growing children.
Height may be negatively affected by the low-fat diet or the
disease itself, and there is a risk for weight gain with high
carbohydrate intake, short fasting periods and continuous
night feeds. In addition, a rapid weight gain may result in
acceleration in height. This study was designed to examine
how the Swedish dietary treatment affects growth, height,
and weight development in children with LCHAD deficiency,
with particular emphasis on growth patterns, final height,
and development of overweight and/or obesity over time.
Materials and Methods
Study Population
Data were retrospectively collected from 10 patients. The
age at diagnosis varied between 2 days and 13 months
(mean 6.1 months). One patient was diagnosed in the
neonatal period before any symptoms had developed
because of a family history. The oldest patient has been
treated for more than 20 years. The diagnosis was based on
increased levels of 3-OH dicarboxylic acids in urine and
3-OH fatty acids in plasma and was confirmed by mutation
analysis. Seven patients were homozygous for the common
LCHAD deficiency mutation G1528C; the other three were
compound heterozygous for G1528C.
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The study protocol was approved by the Ethics Commit-
tee, and informed consent was given by the patients and
families.
Clinical Follow-Up
The patients were followed regularly at our centers.
Information on height, weight, and biochemical parameters
(plasma 3-OH fatty acids, plasma carnitine, liver enzymes,
creatine kinase, and fatty acid profile) was collected and
analyzed. Information on clinical presentation and follow-
up was collected from the medical records. The number of
episodes when the child had fever or muscular pain and had
been treated with extra carbohydrate intake, either orally at
home or as glucose infusions at home, were noted (Table 1).
Dietary Treatment
Dietary treatment with a low intake of LCT fat was
commenced at the time of the diagnosis in all children.
The amount of LCT fat in grams was adjusted according to
Swedish nutritional minimum requirement recommen-
dations in correlation with age (Shaw and Lawson 2001).
Parents were taught how to calculate their child’s LCT
intake in grams, to ensure that it did not exceed the
maximum prescribed quantity. The carbohydrate and
protein intake was not adjusted in detail. Changes in weight
or height curves were followed to assess the caloric intake.
Observed stagnation or acceleration in weight was compen-
sated for by a moderate increase or reduction of the
carbohydrate and protein intake. In addition, the parents
were asked to complete food diaries at least once yearly
with records of everything their child ate, specified in
grams, during 3 consecutive days.
Sufficient amounts of essential fatty acids were given
according to Swedish recommendations, predominantly as
walnut oil containing a minimum of nonessential fats. The
majority of the children (8 out of 10) received docosahex-
aenoic acid (DHA) supplementation to maintain DHA
plasma levels just above or within the upper reference
range. In addition, the diet was enriched with vitamins and
minerals. All but one of the children had a percutaneous
gastrostomy (PEG) with continuous night feeds, predomi-
nantly given as a low-fat formula containing whey protein,
carbohydrates, MCT fat, vitamins, minerals, and trace
elements. The fasting periods were limited to 3–4 h,
depending on age. In order to reduce lipolysis, two children
were given uncooked corn starch. During febrile infections,
a carbohydrate-rich supplement or intravenous glucose
infusion was administered. Only patients with a carnitine
deficiency were given supplements of 25–50 mg/kg/day,
which were omitted during acute decompensations.
Growth
Height and weight were measured and compared to
Swedish reference data (Wikland et al. 2002) and plotted
as height SDS and BMI SDS. For children born preterm,
height and weight SDS were corrected for gestational age
up to age 2 years. Overweight was defined as iso-
BMI  25 kg/m2 and obesity as iso-BMI  30 kg/m2
(Cole et al. 2000; Han et al. 2010; Lindgren et al. 1995).
Parental heights were recorded and the target heights (TH)
(Tanner et al. 1970) were calculated. In order to assess
whether the children achieved the final height (FH)
according to their genetic potential, TH SDS was compared
to FH SDS. The age at menarche for the girls and their
mothers was recorded. The onset of puberty for the boys
was assessed by observing start and duration of the pubertal
growth spurt in the charts. For patients who had reached
FH, the height of the pubertal spurt was calculated and
compared with the Tanner reference (28  8 cm for the
boys, 25  8 cm for the girls) (Tanner et al. 1976). Birth
weight SDS were obtained from the growth charts while the
exact SDS of height, weight, BMI, and target height were
calculated by the NordiNet® IOS pediatric database and the
results used to generate the SDS growth curves.
Results
Clinical Follow-Up
After the confirmed diagnosis and dietary intervention was
started, no patients died. Data of birth weight, pregnancy
complications, symptoms at diagnosis, and number of
episodes with increased carbohydrate intake are listed in
Table 1.
Dietary Treatment
The food diaries showed that the reported fat intake adhered
quite well to the recommended diet. Table 2 illustrates a
characteristic day for a 5-year-old girl with LCHAD
deficiency, following the Swedish recommendations.
Regrettably we were unable to calculate the dietary intake
for the patient group over time, since not enough data was
obtained due to noncompliance and/or missing food diaries.
In order to compare the fat intake in grams to other
recommendations emphasizing fat restriction as E%, the
results from the food diaries of two patients of different age,
gender, weight, physical activity levels, and body composi-
tion were converted to E%. Calculations were done over
several years in the same patients and showed that the
reported intake in grams for the two patients was equivalent
























































































































































































































































































































































































































































































































































































4–5 E% LCT. As expected, the children with LCHAD
deficiency had a lower total fat intake than recommended
for growing children.
Growth
The growth trajectories illustrated that the majority of
patients had an initial height and BMI acceleration after the
diagnosis, followed by a stabilization or deceleration in
height SDS after a couple of years (Figs. 1 and 2). Eight
patients (7 girls, 1 boy; patients 1 and 4–10) developed
overweight before 6 years of age. Six patients (5 girls,
1 boy; patients 1, 4–6, 8, and 10) had an iso- BMI of
slightly more than 30 kg/m2 for a 1–5-year period. Seven
patients (5 girls, 2 boys; patients 1, 2, 5, 6, and 8–10) had
an iso-BMI  25 kg/m2, and one of these patients (patient
10) had an iso BMI  30 kg/m2 at the latest assessment.
The other three patients (2 girls, 1 boy; patients 3, 4, and 7)
had normal weight for age at the most recent examination
(Figure 2). No patients were underweight at any time, apart
from patient 2 who showed a different growth pattern than
the other patients (Fig. 2), with a fall in BMI below –
2 SDS at 3 years of age, after which the patient showed a
markedly increased weight gain. He had poor appetite and
was physically very active throughout his younger years,
followed by recurrent episodes of muscular pain and
elevated CK levels treated with increased energy intake.
In addition, this patient had a combination of complex
treatment resistant seizures. Following gastrostomy at
5 years of age and commencement with vigabatrin, his
weight increased, a side effect known to be associated with
vigabatrin therapy (Chadwick 1999). Patient 1 had a rapid
weight gain for a short period (+ 4 SDS between 3 and
6 years) when she had recurrent infections.
Five patients had reached FH (patients 1–5). FH was
within  1.0 SDS of TH in three patients (patients 2, 4,
and 5) and slightly below target in two patients (patients 1
and 3). Patient 3 had critical hypoglycemia at the time of
diagnosis and developed neurological sequele, contractures,
and epilepsy with poor seizure control.
Four out of ten patients (1,4,5,9) (40 %) had a BW
between 1.8 and 2.3 SDS when correcting for gesta-
tional age (Table 1). Three patients had had menarche
(patients 1, 4, 5). One girl (patient 1) had an early puberty,
treated with a GnRH agonist between 8 and 10 years of
age. Her pubertal growth spurt was normal (24 cm) (Tanner
et al. 1976) but she did not reach TH. Patient 4 had
menarche at the same age as her mother (at 14 years) while
patient 5 had menarche 2 years earlier than her mother (at
11 years). The onset of puberty for the boys was within the
normal age. One out of five patients (patient 3) had a
subnormal height gain during adolescence, compared to the
Tanner reference (Tanner et al. 1976). Mean female FH was
164 cm, constituting – 0.6 SDS, and mean male FH
183 cm, equal to 0.4 SDS. Mean TH SDS for all patients
was 0.6 SDS, indicating that this patient population was
comparable to the normal population.
Discussion
In this Swedish cohort of ten children with LCHAD
deficiency, growth trajectories showed increased growth
during a period of months to years after the diagnosis,
followed by a period of stable or decelerated growth. The
majority of the patients developed overweight and, in
addition, obesity during various periods. The growth
trajectories were comparable to those of normal children
with overweight or obesity (He and Karlberg 2001). Three
out of five patients reached FH within their TH; conse-
quently, it seems that neither the disorder itself nor the
dietary treatment affected FH negatively.
Table 2 Dietary intake in grams from a standard day for a 5-year-old
girl with an LCHAD deficiency
Time Food Amount (g)











2 pm Fruit yogurt (0.05% fat) 200
Corn flakes 15
Liquigen 10






Skim milk (<0.01%) 175
Liquigen 10
7 pm Banana 110
9 pm to 6 am Monogen (blended) 300
Walnut oil 2.5
Fish oila 1.5
a Providing 330 mg DHA
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The Swedish dietary instructions (Shaw and Lawson
2001) for LCT intake were given in grams, in an attempt to
achieve metabolic control but avoid overfeeding and
obesity. This differs from recent dietary guidelines
(Spiekerkoetter et al. 2009b, 2010; Gillingham et al.
1999) that recommend indicating LCT intake as E%. Hence
calculating grams of fat instead of recommending fat intake
as E% may be an alternative approach to decrease LCT
intake since E% will allow a larger amount of LCT the
higher the total calorie intake is. In order to compare the
intake of LCT fat in patients adhering to the Swedish
recommendations with the generally more common instruc-
tions in E%, we recalculated the food diaries from two
patients. These two examples illustrate that the reported
LCT intake is somewhat lower than that recommended by
Spiekerkoetter et al. (25–30 E% from fat with 20–25 % as
MCT and 5–10 % as LCT) (Spiekerkoetter et al. 2009b) as
well as Gillingham (10–20 E% as MCT and 10 E% from
LCT) (Gillingham et al. 2003). In this retrospective study,
there was no method to really know what the child actually
ingested over time. The nutritional diaries give a subjective
3-day snapshot of the patients’ life, often recorded during
a period when the child was well (Lichtman et al. 1992). In
addition, the available data was not sufficient to allow for
more detailed calculations, but the data retrieved indicated
good compliance with given dietary recommendations.
Previous results indicate that patients with an LCHAD
deficiency may have increased lipolysis as soon as after
3–4 hours of fasting (Halldin et al. 2007) underscoring the
importance of minimizing the fasting periods and recom-
mending night feeds. This differs from the recommenda-
tions by Spiekerkoetter et al., who suggest maximum
fasting periods of 10–12 hours at night from 4 years of
age (Spiekerkoetter et al. 2009b).
In our cohort, six out of ten patients (60 %) were
overweight and one out of ten (10 %) obese at the most
recent assessments. However, six patients had a transient
period of obesity that regressed to overweight as they
became older. In comparison, a Swedish study of healthy
schoolchildren aged 8–9 showed that 11 % of the girls and
15 % of boys were overweight, and 3 % of the girls and
4 % of the boys were obese (Rasmussen et al. 2004). This
indicates that overweight/obesity was overrepresented in































Fig. 1 Height SDS in 10 patients with an LCHAD deficiency. The
dotted vertical line illustrates the time at which all patients were
diagnosed and dietary treatment was started (13 months). The growth
trajectories for height SDS show an initial accelerated growth in
childhood after the time of diagnosis
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show an obesity rate of 30 % in nine children with LCHAD
deficiency (Gillingham et al. 2007), while Lund et al. do
not report the weight development of their patients (Lund
et al. 2010).
It is noteworthy that the severe lipid restriction results in
a relatively high carbohydrate content which is interesting
from an overweight/obesity perspective. There is emerging
evidence that the rate of carbohydrate absorption after a
meal, the glycaemic index, may affect weight gain (Brand-
Miller et al. 2009). Foods with high glycaemic index that
result in an initial period of high blood glucose and insulin
levels, followed by a rapid fall in blood glucose is often
associated with reduced satiety and excessive caloric intake
(Ludwig 2002, 2007). On the other hand, low GI foods
produce a more consistent blood glucose and insulin release
and consequently increased satiety, but may in addition
promote fat oxidation and decrease lipogenesis (Brand-
Miller and Buyken 2012; Kong et al. 2011; Thomas et al.
2007). This subject warrants future studies since it is not
obvious how the glycaemic index could be used to improve
the situation for LCHAD patients.
Overweight/obesity in childhood is associated with
accelerated linear growth, earlier pubertal maturity, and a
subnormal height gain in adolescence, and in the end not
affecting FH (Dunger et al. 2005; Garn and Haskell 1959;
He and Karlberg 2001; Shalitin and Phillip 2003). Two out
of three girls in our study had an early puberty, possibly
caused by the increased weight gain in childhood. A rapid
weight gain in infancy may also cause insulin resistance
(Dunger et al. 2005). To the best of our knowledge, insulin
sensitivity has not been studied in LCHAD-deficient
patients, although one study suggests that children with
LCHAD/MTP-deficiency and adiposity have normal insulin
sensitivity based on normal insulin secretion (Gillingham
et al. 2007). Three out of five patients reached FH within
1 SDS of TH and mean FH was – 0.6 SDS (girls)/0.4 SDS
(boys), which indicated adequate growth in the majority of
patients. Two patients did not reach TH, likely due to
complicating factors other than the fatty acid disorder itself,
as one patient developed early puberty and the other had


























Fig. 2 BMI SDS in 10 patients with LCHAD deficiency. The dotted
vertical line illustrates the time at which all patients were diagnosed
and started on dietary treatment (13 months). Growth trajectories for
BMI SDS show early BMI acceleration after the time of diagnosis and
development of overweight/obesity in childhood. The majority of
patients have a BMI SDS of over  1 at the latest assessments
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Earlier reports have demonstrated increased frequencies of
IUGR of 47 % (Tyni et al. 1998a) and 43 % (Yang et al.
2002) in patients with LCHAD/MTP defects, not only
explained by preeclampsia-related conditions. In this cohort,
four out of ten patients (40 %) had some degree of IUGR.
Preeclampsia developed in three out of ten pregnancies
(30 %) (Table 1), which is consistent with several previous
reports (den Boer et al. 2002; Tyni et al. 1998a; Yang et al.
2002). Birth weight is significantly associated with child-
hood growth (Li et al. 2004). However, this could not be
studied in this small patient population.
The causes of obesity and overweight are certainly
multifactorial, although the primary determinants of weight
gain are excessive caloric intake or insufficient physical
activity (Prentice and Jebb 1995) (Han et al. 2010). In
LCHAD-deficient patients, there is an obvious risk for
overfeeding prompted by the dietary treatment per se, the
frequency of meals during the day, the continuous night
feeds and short fasting periods as well as altered resting
energy expenditure due to the inborn error of metabolism.
Parents learning that their child has a disorder with risk for
hypoglycemic episodes, treated with frequent feeds, may
initially feel insecure and overcompensate resulting in
increased weight gain following diagnosis. Children with
LCHAD deficiency may be less physically active due to
muscular weakness or pain and/or neurological deficits. The
increase in BMI seen throughout early childhood may also
reflect the increased caloric intake during infections. In the
general population, children with parents that have an
elevated BMI are at risk of developing obesity (Danielzik
et al. 2002; Xu et al. 2011). The children with LCHAD
deficiency differ in that they have a specific diet, different
from the rest of the family. However, it is likely that
hereditary and/or social factors such as attitude to food and
physical activity may influence weight development in the
patient when other family members have an increased BMI.
Childhood obesity is associated with a higher risk of
morbidity in childhood and adolescence (Daniels 2009)
with serious disability and premature death in adulthood
(Bjorge et al. 2008; Reilly and Kelly 2010). Planned weight
reduction is difficult in patients with an LCHAD deficiency,
since this is associated with a risk of metabolic decompen-
sation (Gillingham et al. 1999; Hagenfeldt et al. 1990;
Halldin et al. 2007; Houten and Wanders 2010). Hence, it is
challenging but crucial for the clinician to prevent the
development of overweight and obesity. It is necessary to
adjust the diet and energy intake and encourage physical
activity to achieve normal weight without the development
of complications. In conformity with the care of patients
with other inborn errors of metabolism, it is essential to
evaluate whether the therapeutic effects on the derange-
ments of the disorder justify a strict dietary regimen or
whether the patients would have a better quality of life with
more liberal dietary recommendations.
Conclusions
Dietary treatment in LCHAD deficiency presents a chal-
lenge. The necessity of frequent feeds, high contents of
carbohydrates, and periods of high energy intake to
maintain good metabolic control increases the risk of
overweight and obesity. In this cohort of LCHAD-deficient
patients, an accelerated growth during the first years after
the diagnosis and start of treatment followed by a period of
stable or decelerated growth was seen. The patients
developed overweight more often than in the general
population, but few were obese despite overnight feeds.
To improve metabolic control and weight development, we
recommend frequent regular clinical follow-ups and extra
vigilance concerning diet and weight. It is possible that
giving recommendations for LCT fat intake in grams
instead of E% may facilitate weight control and it is
important to evaluate the appropriate length of fasting
periods to avoid overcompensation.
Acknowledgments We thank the patients and their families for
taking part in the study. We are indebted to nurses Jenny Gårdman
and dieticians Gunn Nyberg, Agnes Pal, and Christina Eklund for
their skillful know-how and clinical assessments. This research has
been financially supported by the regional agreement on medical
training and clinical research (ALF) between Stockholm County
Council and the Karolinska Institute, the Sven Jerring Foundation,
the Samariten Foundation, the Child Care Society, and the Vera
Ekstr€om Foundation.
References
Bennett MJ, Rinaldo P, Strauss AW (2000) Inborn errors of mitochon-
drial fatty acid oxidation. Crit Rev Clin Lab Sci 37:1–44
Bjorge T, Engeland A, Tverdal A, Smith GD (2008) Body mass index
in adolescence in relation to cause-specific mortality: a follow-up
of 230,000 Norwegian adolescents. Am J Epidemiol 168:30–37
Brand-Miller J , McMillan-Price J , Steinbeck K , Caterson I (2009)
Dietary glycemic index: health implications. J Am Coll Nutr
28 Suppl:446S–449S
Brand-Miller J, Buyken AE (2012) The glycemic index issue. Curr
Opin Lipidol 23:62–67
Chadwick D (1999) Safety and efficacy of vigabatrin and carbamaze-
pine in newly diagnosed epilepsy: a multicentre randomised
double-blind study. Vigabatrin European Monotherapy Study
Group. Lancet 354:13–19
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a
standard definition for child overweight and obesity worldwide:
international survey. Brit Med J 320:1240–1243
Daniels SR (2009) Complications of obesity in children and
adolescents. Int J Obes (Lond) 33(Suppl 1):S60–65
88 JIMD Reports
Danielzik S, Langnase K, Mast M, Spethmann C, Muller MJ (2002)
Impact of parental BMI on the manifestation of overweight
5–7 year old children. Eur J Nutr 41:132–138
den Boer ME, Wanders RJ, Morris AA, IJlst L, Heymans HS, Wijburg
FA (2002) Long-chain 3-hydroxyacyl-CoA dehydrogenase defi-
ciency: clinical presentation and follow-up of 50 patients.
Pediatrics 109:99–104
Dunger DB, Ahmed ML, Ong KK (2005) Effects of obesity on
growth and puberty. Best Pract Res Clin Endocrinol Metab
19:375–390
Fahnehjelm KT, Holmstrom G, Ying L et al (2007) Ocular character-
istics in 10 children with long-chain 3-hydroxyacyl-CoA dehy-
drogenase deficiency: a cross-sectional study with long-term
follow-up. Acta Ophthalmol Scand 86(3):329–337
Garn SM, Haskell JA (1959) Fat and growth during childhood.
Science 130:1711–1712
Gillingham M, Van Calcar S, Ney D, Wolff J, Harding C (1999)
Dietary management of long-chain 3-hydroxyacyl-CoA dehydro-
genase deficiency (LCHADD). A case report and survey. J
Inherit Metab Dis 22:123–131
Gillingham MB, Connor WE, Matern D et al (2003) Optimal dietary
therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase defi-
ciency. Mol Genet Metab 79:114–123
Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding
CO (2007) Effects of higher dietary protein intake on energy
balance and metabolic control in children with long-chain
3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional
protein (TFP) deficiency. Mol Genet Metab 90:64–69
Hagenfeldt L, von Dobeln U, Holme E et al (1990) 3-Hydroxydi-
carboxylic aciduria–a fatty acid oxidation defect with severe
prognosis. J Pediatrics 116:387–392
Hagenfeldt L, Venizelos N, von Dobeln U (1995) Clinical and
biochemical presentation of long-chain 3-hydroxyacyl-CoA
dehydrogenase deficiency. J Inherit Metab Dis 18:245–248
Halldin MU, Forslund A, von Dobeln U, Eklund C, Gustafsson J
(2007) Increased lipolysis in LCHAD deficiency. J Inherit Metab
Dis 30:39–46
Han JC, Lawlor DA, Kimm SY (2010) Childhood obesity. Lancet
375:1737–1748
He Q, Karlberg J (2001) BMI in childhood and its association with
height gain, timing of puberty, and final height. Pediatric research
49:244–251
Houten SM, Wanders RJ (2010) A general introduction to the
biochemistry of mitochondrial fatty acid beta-oxidation. J Inherit
Metab Dis 33:469–477
IJlst L, Wanders RJ, Ushikubo S, Kamijo T, Hashimoto T (1994)
Molecular basis of long-chain 3-hydroxyacyl-CoA dehydroge-
nase deficiency: identification of the major disease-causing
mutation in the alpha-subunit of the mitochondrial trifunctional
protein. Biochim Biophys Acta. Dec 8;1215(3):347–350
IJlst L, Ruiter JPN, Hoovers JMN, Jakobs ME, Wanders RJ (1996)
Common missense mutation G1528C in long-chain 3-hydroxyacyl-
CoA dehydrogenase deficiency - Characterization and expression
of the mutant protein, mutation analysis on genomic DNA and
chromosomal localization of the mitochondrial trifunctional protein
alpha subunit gene. J Clin Invest 98:1028–1033
Kong APS, Chan RSM, Nelson EAS, Chan JCN (2011) Role of low-
glycemic index diet in management of childhood obesity. Obesity
Reviews 12:492–498
Li L, Manor O, Power C (2004) Early environment and child-to-adult
growth trajectories in the 1958 British birth cohort. Am J Clin
Nutr 80:185–192
Lichtman SW, Pisarska K, Berman ER et al (1992) Discrepancy
between self-reported and actual caloric-intake and exercise in
obese subjects. New Engl J Med 327:1893–1898
Lindgren G, Strandell A, Cole T, Healy M, Tanner J (1995) Swedish
population reference-standards for height, weight and body-mass
index attained at 6 to 16 years (girls) or 19 years (boys). Acta
Paediatrica 84:1019–1028
Ludwig DS (2002) The glycemic index: physiological mechanisms
relating to obesity, diabetes, and cardiovascular disease. JAMA
287:2414–2423
Ludwig DS (2007) Clinical update: the low-glycaemic-index diet.
Lancet 369:890–892
Lund AM, Skovby F, Vestergaard H, Christensen M, Christensen E
(2010) Clinical and biochemical monitoring of patients with
fatty acid oxidation disorders. J Inher Metabolic Dis
33:495–500
Potter BK, Little J, Chakraborty P et al (2012) Variability in the clinical
management of fatty acid oxidation disorders: results of a survey
of Canadian metabolic physicians. J Inherit Metab Dis 35:115–123
Prentice AM, Jebb SA (1995) Obesity in Britain: gluttony or sloth?
BMJ 311:437–439
Rasmussen F, Eriksson M, Bokedal C, Elinder L (2004) [Fysisk
aktivitet, matvanor, €overvikt och sj€alvk€ansla bland ungdomar. In:
Rapport/Epidemiologiska enheten Samh€allsmedicin, Stock-
holmsl€ans landsting (eds) Epidemiologiska enheten, Samh€alls-
medicin Statens folklh€alsoinstitut, Stockholm]
Reilly JJ, Kelly J (2010) Long-term impact of overweight and obesity
in childhood and adolescence on morbidity and premature
mortality in adulthood: systematic review. Int J Obes (Lond)
35(7):891–898
Saudubray JM, Martin D, de Lonlay P et al (1999) Recognition and
management of fatty acid oxidation defects: a series of 107
patients. J Inherit Metab Dis 22:488–502
Shalitin S, Phillip M (2003) Role of obesity and leptin in the pubertal
process and pubertal growth–a review. Int J Obes Relat Metab
Disord 27:869–874
Shaw V, Lawson M (2001) Clinical paediatric dietetics. Blackwell
Science, Oxford
Sims HF, Brackett JC, Powell CK et al (1995) The molecular basis of
pediatric long chain 3-hydroxyacyl-CoA dehydrogenase defi-
ciency associated with maternal acute fatty liver of pregnancy.
Proc Natl Acad Sci U S A 92:841–845
Spiekerkoetter U, Lindner M, Santer R et al (2009a) Management and
outcome in 75 individuals with long-chain fatty acid oxidation
defects: results from a workshop. J Inherit Metab Dis
32:488–497
Spiekerkoetter U, Lindner M, Santer R et al (2009b) Treatment
recommendations in long-chain fatty acid oxidation defects:
consensus from a workshop. J Inherit Metab Dis 32:498–505
Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F,
Wilcken B (2010) Current issues regarding treatment of
mitochondrial fatty acid oxidation disorders. J Inherit Metab
Dis 33:555–561
Tanner JM, Goldstein H, Whitehouse RH (1970) Standards for
children’s height at ages 2–9 years allowing for height of
parents. Arch Disease Childhood 45:755–762
Tanner JM, Whitehouse RH, Marubini E, Resele LF (1976) The
adolescent growth spurt of boys and girls of the Harpenden
growth study. Ann Hum Biol 3:109–126
Thomas DE, Elliott EJ, Baur L (2007) Low glycaemic index or low
glycaemic load diets for overweight and obesity. Cochrane
Database Syst Rev CD005105
Tyni T, Palotie A, Viinikka L et al (1997) Long-chain 3-hydroxyacyl-
coenzyme A dehydrogenase deficiency with the G1528C
mutation: clinical presentation of thirteen patients. J Pediatrics
130:67–76
Tyni T, Ekholm E, Pihko H (1998a) Pregnancy complications are
frequent in long-chain 3-hydroxyacyl-coenzyme A dehydroge-
nase deficiency. Am J Obst Gynecol 178:603–608
JIMD Reports 89
Tyni T, Kivela T, Lappi M, Summanen P, Nikoskelainen E, Pihko H
(1998b) Ophthalmologic findings in long-chain 3-hydroxyacyl-
CoA dehydrogenase deficiency caused by the G1528C mutation:
a new type of hereditary metabolic chorioretinopathy. Ophthal-
mology 105:810–824
Wanders RJ, Duran M, IJlst L et al (1989) Sudden infant death and
long-chain 3-hydroxyacyl-CoA dehydrogenase. Lancet 2:52–53
Wanders RJ, IJlst L, van Gennip AH et al (1990a) Long-chain
3-hydroxyacyl-CoA dehydrogenase deficiency: identification of
a new inborn error of mitochondrial fatty acid beta-oxidation.
J Inherit Metab Dis 13:311–314
Wanders RJ, van Roermund CW, Schutgens RB et al (1990b) The
inborn errors of peroxisomal beta-oxidation: a review. J Inherit
Metab Dis 13:4–36
Wikland KA, Luo ZC, Niklasson A, Karlberg J (2002) Swedish
population-based longitudinal reference values from birth to
18 years of age for height, weight and head circumference. Acta
Paediatrica 91:739–754
Wilcken B, Leung K, Hammond J, Kamath R, Leonard JV (1993)
Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A
dehydrogenase deficiency. Lancet 341:407–408
Xu L, Dubois L, Burnier D, Girard M, Prud'homme D (2011) Parental
overweight/obesity, social factors, and child overweight/obesity
at 7 years of age. Pediatr Int 53:826–831
Yang Z, Zhao Y, Bennett MJ, Strauss AW, Ibdah JA (2002) Fetal
genotypes and pregnancy outcomes in 35 families with mito-
chondrial trifunctional protein mutations. Am J Obst Gynecol
187:715–720
90 JIMD Reports
